drugset
drugset / Trial / NCT00456937

Escitalopram in Schizophrenia in OCD- Open Label Study

NCT00456937 ↗

Phase 4 Completed 15 enrolled BeerYaakov Mental Health Center Lundbeck Israel · collab
Non-randomizedSingle-groupOpen-label

Summary

SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology

Timeline

Start
2006-07
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 20 mg —

Indications

schizophrenia